Inclusion Criteria:

- 18 years of age or older

- Diagnosis of metastatic pancreatic cancer; subjects must have measurable, or
evaluable disease that is histologically confirmed

- Karnofsky performance status of ≥ 60

- Subjects must have failed 1st line gemcitabine treatment for metastatic pancreatic
cancer:

o An alternate chemotherapeutic agent is an acceptable substitute as 1st line therapy
in the event that the subject was intolerant to, or ineligible to receive
gemcitabine.

- ≥2 weeks elapsed from the completion of previous chemotherapy, and subjects must have
recovered or be at new stable baseline from any related toxicities

Exclusion Criteria:

- More than 1 prior chemotherapy regimen (not including adjuvant therapy) for
metastatic disease

- Evidence of CNS metastases (unless stable for > 3 months) or history of uncontrolled
seizures

- Ongoing radiation therapy or prior radiation therapy administered as a second-line
treatment

- Other active malignancy except basal or squamous carcinoma of the skin

- Inability to swallow food or any condition of the upper GI tract that precludes
administration of oral medications

- Inadequate renal, hepatic and bone marrow function demonstrated by clinical
observations and/or laboratory assessments